


**Sankyo Pharma** started its journey by commercializing compounds created through its biological material extraction, fermentation, and other biotechnologies, such as taka-diastase, adrenaline, and orizantin, and eventually created numerous antibiotic drugs. Through its fermentation technology, Sankyo developed pravastatin, a drug that arose from the early statin compounds that were created by Sankyo and that revolutionized the world of medicine as antihyperlipidemic agents. Sankyo also discovered olmesartan, an organic synthetic drug.

# The History of Daiichi Sankyo



**Daiichi Pharmaceutical** began using its organic synthesis technologies to produce salvarsan, a pioneering chemotherapeutic drug. Daiichi also commercialized tranexamic acid, which is once again garnering attention for its antiplasmin effects (hemostasis and anti-inflammatory effects), and succeeded in developing and launching ticlopidine in Japan, which opened the doors for antiplatelet therapies in the cardiovascular field. Levofloxacin left a mark on the history of not only Japan but also the entire world with its broad spectrum of antibacterial activity.



**TAKA-DIASTASE®**  
Discovered by Dr. Jokichi Takamine, digestive enzyme Taka-Diastase® launched in 1899. This was the foundation product that launched Sankyo Co., Ltd.



**DR. UMETARO SUZUKI**  
In 1910, Dr. Umetaro Suzuki, a future Sankyo scientific adviser, made the world's first discovery of vitamin B1 and established a foundation for the theory of vitamins.



**DR. JOKICHI TAKAMINE**  
In 1912, world-famous chemist and our company's first president Dr. Jokichi Takamine, orchestrated the gift of 3,000 cherry trees from Mayor Yukio Ozaki of Tokyo to the city of Washington, D.C. as a symbol of harmony between our two nations.



**ADRENALIN**  
Adrenalin®, an adrenal cortex hormone agent, launched in 1902.



**CHLOROMYCETIN**  
Manufactured in 1951, Chloromycetin® was the first antibiotic produced in Japan.



**PREVASTIN**  
Pravastatin, (product name Mevalotin), launched in 1989 was a globally groundbreaking antihyperlipidemic agent.



**OLMESARTAN**  
Olmesartan (Benicar® in the U.S. and Olmetec® in Germany), launched in 2002. An antihypertensive agent; olmesartan would later be launched throughout Europe and the world.

## 2013

Launched **Injectafer®** (ferric carboxy-maltose injection), an IV iron replacement agent to treat iron deficiency anemia in adults. First IV infusion product marketed by Daiichi Sankyo, Inc. (2017)

## 2014

Daiichi Sankyo Group acquires **Ambit** and adds to R&D oncology portfolio

Launched **MorphaBond™ ER** (morphine sulfate) extended-release tablets, a pain management medication, in a co-promotion with Inspirin Delivery Sciences, LLC

Daiichi Sankyo, Inc. relocates their **U.S. headquarters** to Basking Ridge, New Jersey

Daiichi Sankyo, Inc. launches **Commitments in Pain Care**



Daiichi Sankyo Group acquires **Plexxikon** and enters U.S. cancer market

Launched **Movantik®** (naloxegol), an opioid-induced constipation (OIC) agent for adults with chronic non-cancer pain, in a co-promotion with AstraZeneca

Launched **Savaysa®** (edoxaban), an oral factor Xa inhibitor

## 2015

## Daiichi-Sankyo cancerenterprise

Daiichi Sankyo Co., Ltd. establishes **Cancer Enterprise** to leverage innovative science and push beyond traditional thinking to create meaningful treatments for cancer patients.

## 2016



**DR. KATSUZAEMON KEIMATSU**  
Dr. Katsuzaeon Keimatsu and five others founded Arsemin Shokai, later Daiichi Pharmaceutical, in 1915.



**SEINOSUKE SHIBATA**  
In 1918 the company's name changed to Daiichi Pharmaceutical Co., Ltd. and Seinosuke Shibata was appointed its first president.



**ADRENALINE (BOSMIN)**  
Adrenaline (product name Bosmin) a synthesized adrenaline treatment for vasoconstriction/hemostasis and asthma, was launched in 1921 and became Daiichi's longest marketed product.



**TRANEXAMIC ACID**  
Tranexamic acid (product name Transamin), an antiplasmin medicine, was launched in 1965.



**PATECS**  
In 1966, Daiichi launched Patecs®, the first form-fitting pain relief patch, which is still sold in Japan by Daiichi Sankyo's over-the-counter subsidiary company.



**OFLOXACIN**  
In 1983 Daiichi signed an out-licensing agreement for ofloxacin (product name Tarivid®), a broad-spectrum antibacterial agent, with Johnson & Johnson of the U.S. and Hoechst of Germany.



**LEVOFLOXACIN**  
Levofloxacin (product name Cravit), a broad spectrum oral antibacterial agent was launched in 1993.